The Data Availability statement for this paper is incorrect. The publisher apologizes for the error. The correct statement is: Data are available upon request at vivli.org. Access to the data is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org. In your request, please include the following accession/reference numbers so that we can identify the dataset you're trying to access: NCT01246986.
Reference
- 1. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. (2020) Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE 15(3): e0222259. https://doi.org/10.1371/journal.pone.0222259 pmid:32210440
Citation: The PLOS ONE Staff (2020) Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE 15(6): e0235580. https://doi.org/10.1371/journal.pone.0235580
Published: June 25, 2020
Copyright: © 2020 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.